ヴァルネヴァに関するコメント

Valneva predicts a lower cash burn this year than in 2023, with its commercial business expected to be cash-flow positive and significantly fund the company's R&D from 2025. The company also foresees lower R&D expenses, narrowing guidance to €60 million to €75 million.

Valneva's new governance structure is expected to improve the company's leadership effectiveness and efficiency according to CEO Thomas Lingelbach, while Anne-Marie Graffin expresses her commitment to deliver on the company's ambition and growth trajectory in the interest of all stakeholders.

CEO Thomas Lingelbach sees industry-standard governance as a boost for Valneva's leadership efficacy and efficiency. Departing chairman Frederic Grimaud has faith in the organization's chikungunya and Lyme disease ventures progress.

Leading COVID-19 vaccine developers continued to decline towards Monday's close after President Joe Biden said that the pandemic is a thing of the past despite ongoing concerns related to the virus.
"The pandemic is over," he said Sunday during a 60 Minutes interview on the sidelines of the Detroit auto show, adding, "We still have a problem with COVID. We're still doing a lot of work on it. But the pandemic is over."
Shortly after 3:30P...